Resolve Therapeutics is pioneering safe, targeted therapies for underserved patients with autoimmune diseases. Our lead program, RSLV-132, is designed to prevent chronic, systemic inflammation that may cause organ damage and the symptoms associated with autoimmune diseases. RSLV-132 is a first-in-class RNase-Fc fusion protein being developed to treat patients with lupus and Sjögren’s syndrome. We are conducting a Phase 2a study of RSLV-132 in lupus and will be initiating a Phase 3 study in Sjögren’s syndrome in 2020.

Management Team

Founder and Chief Executive Officer

Jim Posada, Ph.D., MBA, is founder and Chief Executive Officer…

Chairman of the Board of Managers

Dr. Peter Kiener is an experienced veteran in pharmaceutical…

Dr. Dan Burge has provided clinical and strategic consulting services to…

Regulatory

Jeff Fellows is a seasoned pharmaceutical industry professional …

Regulatory Lead - Chemistry, Manufacturing and Controls

Dr. Raj Dua oversees regulatory functions, including the process…

Clinical Advisory Board

The Feinstein Institute

Head Rheumatology, Univ. Washington

Northwell Health

Oklahoma Res. Foundation